View in EDS

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.

Saved in:
Bibliographic Details
Title: A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.
Authors: Nikolcheva T; Product Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: tania.nikolcheva@roche.com., Pagano G; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland; University of Exeter Medical School, London, UK., Pross N; Product Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Simuni T; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Marek K; Institute for Neurodegenerative Disorders, New Haven, CT, USA., Postuma RB; Department of Neurology, McGill University, and Montreal Neurological Institute, Montreal, Canada., Pavese N; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK., Stocchi F; University San Raffaele Roma and the Institute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome, Italy., Seppi K; Department of Neurology, Medical University Innsbruck, Innsbruck, Austria., Monnet A; Product Development Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Shariati N; Product Development Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Ricci B; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Rutten-Jacobs L; Product Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Respondek G; Product Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Kustermann T; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Taylor KI; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Trundell D; Product Development Data Science, Roche Products Ltd, UK., Fontoura P; Product Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Doody R; Product Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Genentech USA Inc., San Francisco, USA., Svoboda H; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Roche Diagnostics GmbH, Penzberg, Germany., Bonni A; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Corporate Authors: PADOVA Investigators and Prasinezumab Study Group
Source: Parkinsonism & related disorders [Parkinsonism Relat Disord] 2025 Mar; Vol. 132, pp. 107257. Date of Electronic Publication: 2024 Dec 29.
Publication Type: Journal Article; Clinical Trial Protocol
Journal Info: Publisher: Elsevier Science Country of Publication: England NLM ID: 9513583 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5126 (Electronic) Linking ISSN: 13538020 NLM ISO Abbreviation: Parkinsonism Relat Disord Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-5126
DOI:10.1016/j.parkreldis.2024.107257